I breifly read the TH-302 results for their combo trial and noticed the pancreatic cancer arm TH-302 + gemcitabine combo trial had a complete response and a number of CR's. I hav no position in THLD at the moement - but would enjoy hearing comments on the results.
19 patients (18 OF 19 WERE REFRACTORY TO PLATINUM) with head and neck cancer received at least two cycles and were evaluable for response. Most were SCCHN patients refractory to previous platinum-based chemotherapy for recurrent/metastatic disease. Partial responses were seen in eight patients (42%) and stable disease (SD) in six (32%). One additional PR and one SD were observed among four patients with malignant melanoma.
The mean overall survival (OS) in 24 treated head and neck cancer patients is more than eight months, with four patients currently still alive. The mean OS of the patients experiencing PR and PR plus SD is statistically significantly greater than the mean survival of those patients experiencing progressive disease (PD) (hazard ratio 0.2, p=0.0249 and hazard ratio 0.27, p=0.04, respectively, with a 95% confidence interval).
It is my understanding that patients were on the treatment for 8 weeks and after that treatment was discontinued while observation continues to date. below is the poster linked.
Market Data 
Markets 
AI
